These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

193 related articles for article (PubMed ID: 38724599)

  • 1. A novel anti-LAG-3/TIGIT bispecific antibody exhibits potent anti-tumor efficacy in mouse models as monotherapy or in combination with PD-1 antibody.
    Dai T; Sun H; Liban T; Vicente-Suarez I; Zhang B; Song Y; Jiang Z; Yu J; Sheng J; Lv B
    Sci Rep; 2024 May; 14(1):10661. PubMed ID: 38724599
    [TBL] [Abstract][Full Text] [Related]  

  • 2. An engineered oncolytic vaccinia virus encoding a single-chain variable fragment against TIGIT induces effective antitumor immunity and synergizes with PD-1 or LAG-3 blockade.
    Zuo S; Wei M; Xu T; Kong L; He B; Wang S; Wang S; Wu J; Dong J; Wei J
    J Immunother Cancer; 2021 Dec; 9(12):. PubMed ID: 34949694
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Development of Anti-human T Cell Immunoreceptor with Ig and ITIM Domains (TIGIT) Monoclonal Antibodies for Flow Cytometry.
    Takei J; Asano T; Nanamiya R; Nakamura T; Yanaka M; Hosono H; Tanaka T; Sano M; Kaneko MK; Harada H; Kato Y
    Monoclon Antib Immunodiagn Immunother; 2021 Apr; 40(2):71-75. PubMed ID: 33900817
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Discovery of a novel anti PD-L1 X TIGIT bispecific antibody for the treatment of solid tumors.
    Xiao Y; Chen P; Luo C; Xu Z; Li X; Liu L; Zhao L
    Cancer Treat Res Commun; 2021; 29():100467. PubMed ID: 34598062
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Hepatocellular Carcinoma Cells Up-regulate PVRL1, Stabilizing PVR and Inhibiting the Cytotoxic T-Cell Response via TIGIT to Mediate Tumor Resistance to PD1 Inhibitors in Mice.
    Chiu DK; Yuen VW; Cheu JW; Wei LL; Ting V; Fehlings M; Sumatoh H; Nardin A; Newell EW; Ng IO; Yau TC; Wong CM; Wong CC
    Gastroenterology; 2020 Aug; 159(2):609-623. PubMed ID: 32275969
    [TBL] [Abstract][Full Text] [Related]  

  • 6. FS118, a Bispecific Antibody Targeting LAG-3 and PD-L1, Enhances T-Cell Activation Resulting in Potent Antitumor Activity.
    Kraman M; Faroudi M; Allen NL; Kmiecik K; Gliddon D; Seal C; Koers A; Wydro MM; Batey S; Winnewisser J; Young L; Tuna M; Doody J; Morrow M; Brewis N
    Clin Cancer Res; 2020 Jul; 26(13):3333-3344. PubMed ID: 32299814
    [TBL] [Abstract][Full Text] [Related]  

  • 7. A novel bispecific nanobody with PD-L1/TIGIT dual immune checkpoint blockade.
    Ma L; Gai J; Qiao P; Li Y; Li X; Zhu M; Li G; Wan Y
    Biochem Biophys Res Commun; 2020 Oct; 531(2):144-151. PubMed ID: 32782142
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Effective Anti-tumor Response by TIGIT Blockade Associated With FcγR Engagement and Myeloid Cell Activation.
    Han JH; Cai M; Grein J; Perera S; Wang H; Bigler M; Ueda R; Rosahl TW; Pinheiro E; LaFace D; Seghezzi W; Williams SMG
    Front Immunol; 2020; 11():573405. PubMed ID: 33117369
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Rapid, sensitive and cost-effective determination of immune checkpoint inhibitor activity using a magnetic bead-based binding assay.
    Meng Q; Fu Y; Li S; Yan Y; Duan D; Anthony DD; Zhu Y; Wu X; Qian F; Wu C
    J Immunol Methods; 2021 Nov; 498():113134. PubMed ID: 34464606
    [TBL] [Abstract][Full Text] [Related]  

  • 10. LAG-3xPD-L1 bispecific antibody potentiates antitumor responses of T cells through dendritic cell activation.
    Sung E; Ko M; Won JY; Jo Y; Park E; Kim H; Choi E; Jung UJ; Jeon J; Kim Y; Ahn H; Choi DS; Choi S; Hong Y; Park H; Lee H; Son YG; Park K; Won J; Oh SJ; Lee S; Kim KP; Yoo C; Song HK; Jin HS; Jung J; Park Y
    Mol Ther; 2022 Aug; 30(8):2800-2816. PubMed ID: 35526096
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Expression of lymphocyte-activating gene 3 and T-cell immunoreceptor with immunoglobulin and ITIM domains in cutaneous melanoma and their correlation with programmed cell death 1 expression in tumor-infiltrating lymphocytes.
    Lee WJ; Lee YJ; Choi ME; Yun KA; Won CH; Lee MW; Choi JH; Chang SE
    J Am Acad Dermatol; 2019 Jul; 81(1):219-227. PubMed ID: 30880064
    [TBL] [Abstract][Full Text] [Related]  

  • 12. PD-1, CTLA-4, LAG-3, and TIGIT: The roles of immune checkpoint receptors on the regulation of human NK cell phenotype and functions.
    Esen F; Deniz G; Aktas EC
    Immunol Lett; 2021 Dec; 240():15-23. PubMed ID: 34599946
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Restoration of T-cell Effector Function, Depletion of Tregs, and Direct Killing of Tumor Cells: The Multiple Mechanisms of Action of a-TIGIT Antagonist Antibodies.
    Preillon J; Cuende J; Rabolli V; Garnero L; Mercier M; Wald N; Pappalardo A; Denies S; Jamart D; Michaux AC; Pirson R; Pitard V; Bagot M; Prasad S; Houthuys E; Brouwer M; Marillier R; Lambolez F; Marchante JR; Nyawouame F; Carter MJ; Baron-Bodo V; Marie-Cardine A; Cragg M; Déchanet-Merville J; Driessens G; Hoofd C
    Mol Cancer Ther; 2021 Jan; 20(1):121-131. PubMed ID: 33277440
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Progress of lymphocyte activation gene 3 and programmed cell death protein 1 antibodies for cancer treatment: A review.
    Li YQ; Chen XM; Si GF; Yuan XM
    Biomol Biomed; 2024 Apr; 24(4):764-774. PubMed ID: 38581716
    [TBL] [Abstract][Full Text] [Related]  

  • 15. TSR-033, a Novel Therapeutic Antibody Targeting LAG-3, Enhances T-Cell Function and the Activity of PD-1 Blockade
    Ghosh S; Sharma G; Travers J; Kumar S; Choi J; Jun HT; Kehry M; Ramaswamy S; Jenkins D
    Mol Cancer Ther; 2019 Mar; 18(3):632-641. PubMed ID: 30587557
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Bispecific T-Cell Engaging Antibodies Against MUC16 Demonstrate Efficacy Against Ovarian Cancer in Monotherapy and in Combination With PD-1 and VEGF Inhibition.
    Yeku OO; Rao TD; Laster I; Kononenko A; Purdon TJ; Wang P; Cui Z; Liu H; Brentjens RJ; Spriggs D
    Front Immunol; 2021; 12():663379. PubMed ID: 33936101
    [TBL] [Abstract][Full Text] [Related]  

  • 17. An Fc-Competent Anti-Human TIGIT Blocking Antibody Ociperlimab (BGB-A1217) Elicits Strong Immune Responses and Potent Anti-Tumor Efficacy in Pre-Clinical Models.
    Chen X; Xue L; Ding X; Zhang J; Jiang L; Liu S; Hou H; Jiang B; Cheng L; Zhu Q; Zhang L; Zhou X; Ma J; Liu Q; Li Y; Ren Z; Jiang B; Song X; Song J; Jin W; Wei M; Shen Z; Liu X; Wang L; Li K; Zhang T
    Front Immunol; 2022; 13():828319. PubMed ID: 35273608
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Repositioning liothyronine for cancer immunotherapy by blocking the interaction of immune checkpoint TIGIT/PVR.
    Zhou X; Du J; Wang H; Chen C; Jiao L; Cheng X; Zhou X; Chen S; Gou S; Zhao W; Zhai W; Chen J; Gao Y
    Cell Commun Signal; 2020 Sep; 18(1):142. PubMed ID: 32894141
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Preclinical Development of the Anti-LAG-3 Antibody REGN3767: Characterization and Activity in Combination with the Anti-PD-1 Antibody Cemiplimab in Human
    Burova E; Hermann A; Dai J; Ullman E; Halasz G; Potocky T; Hong S; Liu M; Allbritton O; Woodruff A; Pei J; Rafique A; Poueymirou W; Martin J; MacDonald D; Olson WC; Murphy A; Ioffe E; Thurston G; Mohrs M
    Mol Cancer Ther; 2019 Nov; 18(11):2051-2062. PubMed ID: 31395688
    [TBL] [Abstract][Full Text] [Related]  

  • 20. PD-1/LAG-3 bispecific antibody potentiates T cell activation and increases antitumor efficacy.
    Shi N; Zhou Y; Liu Y; Zhang R; Jiang X; Ren C; Gao X; Luo L
    Front Immunol; 2022; 13():1047610. PubMed ID: 36518768
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 10.